Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505431 | 0.85 | IRAK4 (0.44) | IRAK4SREBF2HDAC1HDAC6HDAC8 | |
| SCHEMBL13162322 | 0.85 | IRAK4 (0.44) | IRAK4SREBF2HDAC1HDAC6HDAC8 | |
| SCHEMBL29613007 | 0.84 | TGFBR1 (0.42) | IRAK4SREBF2TGFBR1AAK1 | |
| SCHEMBL16698999 | 0.84 | TGFBR1 (0.42) | IRAK4SREBF2TGFBR1AAK1 | |
| SCHEMBL31268286 | 0.84 | IRAK4 (0.43) | IRAK4SREBF2HDAC1HDAC6HDAC8 | |
| SCHEMBL2080592 | 0.84 | IRAK4 (0.43) | IRAK4SREBF2HDAC1HDAC6HDAC8 | |
| SCHEMBL13634380 | 0.82 | TGFBR1 (0.48) | IRAK4SREBF2TGFBR1AAK1 | |
| SCHEMBL13270402 | 0.82 | IRAK4 (0.42) | IRAK4SREBF2HDAC1HDAC6HDAC8 | |
| SCHEMBL3436665 | 0.80 | IRAK4 (0.46) | IRAK4HDAC1HDAC6HDAC8 | |
| SCHEMBL13634775 | 0.80 | IRAK4 (0.40) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | IRAK4 199/4885SREBF2 4721/4885HDAC1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.